CytomX Therapeutics reported an encouraging expansion‑cohort response rate for its masked EpCAM ADC Varsetatug masetecan (Varseta‑M) in advanced colorectal cancer—data that included objective responses and progression‑free survival near seven months at selected doses. The company said updated results will be presented at medical meetings and that it will engage regulators on next steps. Separately, Astellas terminated parts of a six‑year alliance with CytomX, a collaboration that once carried up to ~$1.6–1.7 billion in milestones; CytomX said it is evaluating options to advance targets formerly covered by the deal. Together the developments highlight commercial and development inflection points for next‑generation ADC strategies and the risk‑reward tension in large biopharma partnerships.